Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12851469 | 1.00 | CYP3A4 (0.32) | CYP3A4CYP2D6TSHRNFKB1THPO | |
| SCHEMBL5137869 | 1.00 | CYP3A4 (0.32) | CYP3A4CYP2D6TSHRNFKB1THPO | |
| SCHEMBL10331496 | 0.85 | TRPA1 (0.50) | CYP3A4SMN1; SMN2 | |
| SCHEMBL21067332 | 0.83 | TSHR (0.31) | TSHRSMN1; SMN2 | |
| SCHEMBL23627794 | 0.82 | ARG1 (0.40) | PMP22 | |
| SCHEMBL4782837 | 0.82 | ARG1 (0.40) | PMP22 | |
| SCHEMBL15024999 | 0.82 | ARG1 (0.40) | PMP22 | |
| SCHEMBL20431198 | 0.80 | — | — | |
| SCHEMBL24295875 | 0.80 | NOS2 (0.32) | — | |
| SCHEMBL41166 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702448-B2 | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers | RHYTHM PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20160017001-A1 | PEPTIDE COMPOSITIONS | RHYTHM PHARMACEUTICALS, INC. | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702448-B2 | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers | MC4R, MC1R, MC2R | CYP3A4 4244/4885CYP2D6 4350/4885TSHR 151/4885 |
| US-20160017001-A1 | PEPTIDE COMPOSITIONS | MC4R, MC3R, MC5R | CYP3A4 2889/4885CYP2D6 3486/4885TSHR 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.